Next Article in Journal
Oxidative Stress in Neurodegenerative Disorders: A Key Driver in Impairing Skeletal Muscle Health
Next Article in Special Issue
Electrochemical Nanostructured Aptasensor for Direct Detection of Glycated Hemoglobin
Previous Article in Journal
Exploration of Bromodomain Proteins as Drug Targets for Niemann–Pick Type C Disease
Previous Article in Special Issue
Transient Inflammation of Pancreatic Exocrine Tissue in Autoimmune Diabetes Follows Onset of Islet Damage and Utilizes Heparanase-1
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Maternal Vascular Adaptation in High-Risk Pregnancies: Effects of Early Smoking Cessation on Hemodynamic and Endothelial Function

by
Kaltrina Kutllovci Hasani
1,*,
Mila Cervar-Zivkovic
1,
Ursula Hiden
1,
Adam Saloň
2,
Manurishi Nanda
1,
Bianca Steuber
3,
Katharina Eberhard
4,
Patrick De Boever
5,
Christina Stern
1,
Karoline Mayer-Pickel
1 and
Nandu Goswami
3,6,*
1
Department of Obstetrics and Gynaecology, Medical University of Graz, Auenbruggerplatz 14, 8036 Graz, Austria
2
Vascular Biology Center, Augusta University, Augusta, GA 30912, USA
3
Gravitational Physiology and Aging Research Unit, Division of Physiology and Pathophysiology, Otto Löwi Research Center of Vascular Biology, Immunity and Inflammation, Medical University of Graz, Neue Stiftingtalstrasse 6/V, 8010 Graz, Austria
4
Core Facility Computational Bioanalytic, ICAL University of Graz, Stiftingtalstraße 24/1, 8010 Graz, Austria
5
Research, Innovation & Valorisation Antwerp (RIVA), Antwerp University Hospital, Campus Middelheim, Middelheimlaan 1, 2020 Antwerp, Belgium
6
Centre for Space and Aviation Health, Mohammed Bin Rashid University of Medicine and Health Sciences, Building 14, Dubai Healthcare City, Dubai P.O. Box 505055, United Arab Emirates
*
Authors to whom correspondence should be addressed.
Int. J. Mol. Sci. 2025, 26(12), 5781; https://doi.org/10.3390/ijms26125781
Submission received: 5 May 2025 / Revised: 8 June 2025 / Accepted: 13 June 2025 / Published: 16 June 2025

Abstract

Cardiovascular adaptation is vital for a healthy pregnancy but may be impaired in women at high risk for preeclampsia (PE), a condition marked by endothelial dysfunction. Smoking may lower the PE risk but harms vessels, and the effects of early cessation remain unclear. This prospective cohort study assessed vascular changes in high-risk pregnancies and the potential influence of early smoking cessation. Of 110 women screened for PE in the first trimester, 43 were classified as high-risk: 18 former smokers and 25 lifelong non-smokers. Vascular assessments were performed at 11–16, 24–28, and 34–37 weeks of gestation. Parameters included the carotid–femoral pulse wave velocity (cfPWV), asymmetric dimethylarginine (ADMA), mean arterial pressure (MAP), systolic and diastolic blood pressure (SBP, DBP), heart rate (HR), and retinal vessel calibers (central retinal arteriolar and venular equivalents (CRAE, CRVE)). Serum cotinine confirmed abstinence in former smokers. Across gestation, ADMA (p = 0.034), MAP (p = 0.001), SBP (p = 0.033), DBP (p = 0.004), and HR (p = 0.004) increased, while CRAE (p = 0.016) and CRVE (p = 0.004) narrowed in late pregnancy; cfPWV remained stable (p = 0.783). Non-smokers showed increases in their ADMA (p = 0.020), MAP (p = 0.001), and DBP (p = 0.0001) with no differences between groups. High-risk pregnancies showed vascular changes with similar profiles in former and non-smokers, underscoring the need for broader studies.

1. Introduction

Physiological adaptations during pregnancy include reductions in blood pressure and the total peripheral resistance as well as an increase in cardiac output, changes that are critical for ensuring adequate placental perfusion and optimal fetal growth [1,2]. In pregnancies complicated by preeclampsia (PE), these normal adaptations are disrupted [1]. PE, which affects 2–8% of pregnancies worldwide, typically manifests after 20 weeks of gestation with new-onset hypertension, proteinuria, maternal organ dysfunction, or placental insufficiency [1,2,3].
The underlying pathophysiology of PE is complex and not completely understood but is primarily linked to impaired placental development and resultant endothelial dysfunction [2]. Inadequate trophoblast invasion and insufficient spiral artery remodeling lead to placental hypoperfusion, which in turn triggers systemic endothelial dysfunction through the release of placental-derived factors [4]. This dysfunction is marked by an imbalance of vasoactive substances, diminished nitric oxide bioavailability, increased immune activation, and systemic inflammation, all contributing to the vascular complications observed in PE [4,5,6].
The early identification of women at high risk for PE is vital for timely intervention. First-trimester screening that integrates maternal risk factors with biochemical markers has significantly improved risk stratification [7,8]. Prophylactic low-dose aspirin is recommended for high-risk women, as it has been shown to reduce the incidence of early-onset PE [8]. Despite these advances, routine cardiovascular monitoring during pregnancy is limited, typically relying on brachial blood pressure measurements [3,6]. A more comprehensive assessment, including measures of arterial stiffness, wave reflection, and detailed hemodynamic indices, may improve the prediction and management of PE [9,10]. In this context, non-invasive assessments, such as the carotid–femoral pulse wave velocity (cfPWV) for assessing arterial stiffness [9], the measurement of endothelial biomarkers like asymmetric dimethylarginine (ADMA) [11], retinal microvascular imaging, the central retinal arteriolar equivalent (CRAE), and the central retinal venular equivalent (CRVE) [4], offer promising avenues for a more nuanced understanding of vascular adaptations during pregnancy. Assessing the retinal microvasculature is supported by findings that visual disturbances occur in up to 25% of individuals affected by preeclampsia, exemplifying the transient yet potentially severe complications of the condition. Severe vision loss is rare and typically resolves postpartum [4,5].
Cigarette smoking is a well-established risk factor for endothelial dysfunction, vascular inflammation, atherosclerosis, and thrombosis [12,13,14,15] and is linked to adverse pregnancy outcomes [16,17,18,19]. However, little research has focused on whether high-risk pregnancies following pre-pregnancy smoking cessation still exhibit vascular impairment. Addressing this gap, our study aims to evaluate cardiovascular alterations in high-risk pregnancies while comparing vascular profiles between former smokers and lifelong non-smokers. We hypothesized that markers of arterial stiffness, endothelial dysfunction, and retinal microvascular parameters would deteriorate over the course of pregnancy in high-risk women and that former smokers would exhibit a residual vascular impairment compared to non-smokers, reflecting the long-term effects of smoking despite cessation. This research will provide a comprehensive understanding of cardiovascular adaptations in high-risk pregnancies and the potential for vascular recovery following smoking cessation, ultimately guiding more effective preventive and monitoring strategies for high-risk pregnancies.

2. Results

2.1. Study Population

Between 11 + 0 and 13 + 6 weeks of gestation, a total of 110 pregnant women underwent first-trimester screening for preeclampsia risk. Based on the screening results, 45 were classified as high-risk. Following the exclusion of two pregnancies due to fetal anomalies, 43 women were enrolled in the study for a longitudinal follow-up.
Participants were assessed at three gestational stages: early pregnancy (Visit 1, V1: 11–16 weeks), mid-pregnancy (Visit 2, V2: 24–28 weeks), and late pregnancy (Visit 3, V3: 34–37 weeks). Due to scheduling limitations, not all participants completed all study visits. Measurements were omitted if the participant presented outside the predefined gestational window.
Hemodynamic assessments, including the mean arterial pressure (MAP), systolic and diastolic blood pressure (SBP, DBP), heart rate (HR), and carotid–femoral pulse wave velocity (cfPWV), were available for 33 women at V1. Follow-up completion rates were approximately 70% at V2 and 45% at V3. Serum asymmetric dimethylarginine (ADMA) concentrations were measured in all 43 women at V1 and in 74% and 63% of participants at V2 and V3, respectively. Cotinine was measured at V1 in all participants to biochemically confirm smoking cessation. Retinal microvascular parameters (central retinal arteriolar equivalent [CRAE] and central retinal venular equivalent [CRVE]) were obtained from 29 participants at V1, with corresponding follow-up rates of 79% at V2 and 55% at V3.
The detailed information on parameter-specific sample sizes at each time point is presented in Supplementary Table S1.
Baseline demographic and clinical characteristics are summarized in Table 1. The mean maternal age was 33.2 ± 4.4 years, and the mean body mass index (BMI) was 26.4 ± 5.9 kg/m2. Most women (86.0%) conceived spontaneously, while 14.0% conceived via in vitro fertilization. At delivery, the mean gestational age was 38 ± 2 weeks, and the average birth weight was 3108 ± 574 g. Nulliparity was observed in 37.2% of the cohort. Based on the self-reported smoking history, 18 participants who ceased smoking between weeks 5 and 8 of gestation were classified as former smokers, while 25 were lifelong non-smokers. The cohort was predominantly Caucasian (97.7%), with one participant identified as Black (2.3%).
Pregnancy outcomes included preeclampsia (18.6%), gestational diabetes mellitus (14.0%), and gestational hypertension (14.0%), while 53.5% of participants experienced no complications.

2.2. Longitudinal Changes in Vascular Parameters by Smoking Status

Within the high-risk cohort, 18 women were classified as former smokers and 25 as lifelong non-smokers. Longitudinal analyses using mixed-effects models (REML) revealed differential trends across the gestation in former smokers and non-smokers. Among former smokers, none of the measured parameters showed statistically significant changes across the three visits, although the heart rate (HR, p = 0.057) and systolic blood pressure (SBP, p = 0.177) showed modest variability. In contrast, non-smokers exhibited statistically significant increases in several parameters: ADMA levels (p = 0.020), mean arterial pressure (MAP, p = 0.001), diastolic blood pressure (DBP, p = 0.0001), and a borderline trend in HR (p = 0.050). The retinal vessel calibers (CRAE, CRVE) and carotid–femoral pulse wave velocity (cfPWV) remained stable over time in both groups (Table 2).

2.3. Comparative Vascular Profiles of Former Smokers and Non-Smokers

To further assess whether early smoking cessation influences vascular function, cardiovascular parameters were compared between former smokers and lifelong non-smokers across pregnancy (descriptive data in Supplemental Table S2). At baseline (V1), both groups showed comparable demographic characteristics, including their age (p = 0.312) and BMI (p = 0.579). No statistically significant differences were observed between former smokers and non-smokers for any cardiovascular parameter at V1, V2, or V3.
Across gestation, both groups showed parallel trends in their asymmetric dimethylarginine (ADMA), mean arterial pressure (MAP), systolic and diastolic blood pressure (SBP, DBP), heart rate (HR), carotid–femoral pulse wave velocity (cfPWV), and retinal vessel calibers (CRAE, CRVE). However, non-smokers exhibited a more pronounced increase in their MAP and DBP between mid- and late pregnancy (MAP: from 88.5 ± 9.7 to 105 ± 9.7 mmHg; DBP: from 70.1 ± 9.5 to 83.7 ± 9.7 mmHg), although this did not reach a statistical significance in group comparisons (MAP: p = 0.160; DBP: p = 0.066). All other parameters remained statistically similar between groups at each time point (Figure 1).

2.4. Longitudinal Changes in Vascular and Hemodynamic Parameters

Progressive and statistically significant changes in vascular and hemodynamic parameters were observed throughout gestation in this high-risk pregnancy cohort, despite some participants missing follow-up assessments due to gestational timing constraints.
Serum asymmetric dimethylarginine (ADMA) levels increased significantly across pregnancy, suggesting a gradual decline in endothelial function (p = 0.034; Figure 2A). The mean arterial pressure (MAP) exhibited a biphasic trend, with an initial decline followed by a significant increase in late pregnancy (p = 0.001; Figure 2B). A similar pattern was noted for systolic blood pressure (SBP), which decreased mid-pregnancy and rose again toward term (p = 0.033; Figure 2C). The diastolic blood pressure (DBP) remained relatively stable early on but showed a significant elevation in the third trimester (p = 0.004; Figure 2D). The heart rate (HR) demonstrated a consistent upward trend across all visits (p = 0.004; Figure 2E).
In contrast, the carotid–femoral pulse wave velocity (cfPWV) remained stable over time, indicating no significant change in arterial stiffness during pregnancy (p = 0.783; Figure 2F).
The retinal vessel analysis revealed late gestational narrowing. The central retinal arteriolar equivalent (CRAE) initially increased slightly, then declined significantly in late pregnancy (p = 0.016; Figure 2H). The central retinal venular equivalent (CRVE) followed a similar course, with a late decrease reflecting an increased retinal microvascular resistance (p = 0.004; Figure 2G).
A complete overview of sample sizes and descriptive data for each parameter is provided in Supplementary Table S1.

3. Discussion

This study presents a comprehensive longitudinal evaluation of the maternal vascular adaptation in high-risk pregnancies, with a specific focus on differences between former smokers and lifelong non-smokers. We investigated changes in the endothelial function, hemodynamic indices, arterial stiffness, and retinal microvascular parameters longitudinally across gestation and examined whether the early pregnancy smoking cessation influences these cardiovascular trajectories.
While both groups (former smokers and lifelong non-smokers) were classified as high-risk, the lifelong non-smokers demonstrated significant increases in the mean arterial pressure (MAP), diastolic blood pressure (DBP), and asymmetric dimethylarginine (ADMA) across gestation, changes that may reflect a typical or even exaggerated hemodynamic adaptation associated with the increased cardiovascular demand during pregnancy.
On the other hand, vascular parameters in former smokers remained comparatively constant over the same time frame. The clear patterns point to possible variations in vascular adaptation, even though no statistically significant results by time interactions or between group differences were found. Rather than signifying a better vascular profile, the relative stability seen in former smokers may be due to the long-lasting effects of previous tobacco exposure on the endothelial function.
According to earlier studies, endothelial and hemodynamic alterations, such as increases in ADMA and the MAP, are typical during pregnancy, especially in women who are at risk for hypertensive disorders [20,21,22,23,24]. Despite their high-risk status, the lack of these alterations in former smokers may indicate a lingering vascular modulation after quitting. Furthermore, it is impossible to completely evaluate the direct vascular effects of continuous tobacco use because our cohort did not include women who smoked during pregnancy.
We found progressive increases in the ADMA, blood pressure parameters, and heart rate throughout gestation in the overall high-risk cohort, which is consistent with endothelial dysfunction and accumulating cardiovascular strain. These results are consistent with earlier studies showing that elevated ADMA levels during pregnancy are a sign of endothelial stress [20,22]. On the other hand, the cfPWV stayed constant during pregnancy, indicating a preserved arterial compliance, which could be the result of compensatory mechanisms, like an increased cardiac output or systemic vasodilation [25,26]. According to the retinal microvascular analysis, the CRAE and CRVE narrowed in late pregnancy, indicating increased microvascular resistance. These trends are consistent with those observed in hypertensive pregnancies [27].
Reference values from the literature provide important context, even though our study lacked a comparator group of normotensive, low-risk pregnancies. With only a slight trimester-based variation, the cfPWV normally falls between 5.5 and 7.0 m/s in healthy nulliparous pregnancies [28]. Depending on the gestational age, blood pressure readings typically fall between 95 and 144 mmHg systolic and 55 and 95 mmHg diastolic [29]. Over the course of three trimesters, retinal vessel calibers stay constant, with the CRAE ranging from 140 to 145 µm and the CRVE from 220 to 225 µm [27,30]. Healthy pregnancies have ADMA levels that progressively increase from a mean of 0.51 µmol/L in the first trimester to 0.58 µmol/L in the third. In contrast, preeclampsia-complicated pregnancies have consistently higher levels, reaching 0.68 µmol/L by late gestation, with the most notable difference occurring in the second trimester [31,32].
These normative ranges support the interpretation of our findings, suggesting that the observed vascular changes reflect deviations consistent with a high-risk pregnancy profile, even in the absence of a healthy control group.
There are a few limitations to take into account. First, we did not include a healthy, low-risk control group, which restricts the interpretation of whether the observed patterns are unique to high-risk pregnancies. Second, we did not gather comprehensive data on the smoking intensity or exposure to secondhand smoke, nor did we have baseline vascular measurements before quitting. In addition, passive smoking, known to affect the arterial stiffness and pulse wave analysis [33], was not assessed in this study. Although our study population consisted exclusively of women, sex-specific differences in vascular responses to smoking are well documented [34] and should be acknowledged when interpreting group-based trends. Future studies should employ multi-center designs and include active smokers to fully elucidate these vascular adaptations. Third, the missing data due to the loss to follow-up, particularly at later gestational stages, may have introduced a bias despite the robustness of mixed-effects modeling. Important confounding variables that may affect the vascular function, including stress levels, socioeconomic status, diet, and physical activity, were also not taken into account.

4. Materials and Methods

4.1. Study Sample

This prospective cohort study enrolled high-risk pregnant women between November 2019 and September 2022 at the Department of Obstetrics and Gynecology, Medical University of Graz. All participants provided written informed consent, and this study was conducted in accordance with the Declaration of Helsinki. Ethical approval was granted by the local Ethics Committee (reference number 31-541 ex 18/19), and this study was registered on ClinicalTrials.gov (NCT06645340).
Participants were identified as high-risk for developing PE based on first-trimester screening performed between 11 + 0 and 13 + 6 weeks of gestation [35]. Inclusion criteria were a high-risk classification based on screening, a history of PE, daily administration of 150 mg aspirin, and age ≥18 years. Women with twin pregnancies, fetal anomalies, chronic kidney disease, or those who discontinued aspirin were excluded. Participants were further stratified by smoking history into former smokers (those who quit upon pregnancy confirmation) and non-smokers. Smoking cessation was verified by serum cotinine levels.

4.2. Vascular and Hemodynamic Measurements

Participants underwent three evaluation visits: early (11–16 weeks, V1), mid (24–28 weeks, V2), and late pregnancy (34–37 weeks, V3). To ensure standardization, subjects were instructed to avoid physical exertion and stimulants for 48 h before assessments. Overview of the study flow is illustrated in Figure 3.
High-risk pregnancies were identified via routine preeclampsia (PE) screening at 11 + 0 and 13 + 6 weeks of gestation and enrolled following informed consent and study familiarization. Participants were followed longitudinally at three time points: early pregnancy (V1, 11–16 weeks), mid-pregnancy (V2, 24–28 weeks), and late pregnancy (V3, 34–37 weeks).
At each visit, vascular and hemodynamic parameters were assessed, including arterial stiffness (carotid–femoral pulse wave velocity, cfPWV), blood pressure indices and heart rate (MAP, SBP, DBP, HR), retinal microvascular calibers (CRAE, CRVE), and endothelial function (asymmetric dimethylarginine, ADMA). Serum cotinine levels were measured to assess smoking status. Illustration created using BioRender, (www.biorender.com (accessed on 15 April 2025)).
The study protocol included several measurements.

4.2.1. Screening for Preeclampsia

Performed between 11 + 0 and 13 + 6 weeks of gestation, maternal risk factors (age, weight, height, chronic conditions) and biophysical markers (blood pressure, mean arterial pressure [MAP], Pregnancy-Associated Plasma Protein-A [PAPP-A], Placental Growth Factor [PlGF], and uterine artery Doppler pulsatility index) were assessed; however, these routine clinical screening values were not included in the research dataset and are not reported in the present study. These variables were incorporated into the Fetal Medicine Foundation (FMF) algorithm to identify women at high risk for early-onset PE [22]. Participants who did not meet the high-risk threshold were classified as low-risk and excluded from the study. High-risk participants received daily 150 mg aspirin until 36 weeks of gestation [8].

4.2.2. Arterial Stiffness

Arterial stiffness was assessed using cfPWV measured by the VICORDER® system (SMT medical GmbH & Co. KG, Würzburg, Germany) [36]. After a 10 min rest in a semi-supine position, pressure cuffs were placed at the carotid artery and the upper right thigh, and the distance between these sites was recorded. The cfPWV was calculated automatically in meters per second (m/s), reflecting the speed of the pressure wave generated by cardiac contraction traveling along the arterial tree.

4.2.3. Hemodynamic Parameters

Blood pressure and heart rate (HR) were measured twice during cfPWV assessment, and the average values were used to compute MAP using the formula:
MAP = DBP + (SBP − DBP)/3.

4.2.4. Retinal Microvasculature

Retinal images were acquired with a non-mydriatic digital retinal camera (Optomed Aurora, Optomed Oy, Oulu, Finland). Images centered on the optic disc were analyzed with the semi-automated MONA REVA software, version 2.1.1 developed at VITO (Boeretang, Belgium) [37]. The software algorithm segmented retinal vessels and applied post-processing techniques, including double thresholding, blob extraction, and hole filling, to automatically measure the diameters of retinal arterioles and venules located 0.5 to 1 disc diameter from the optic disc margin. Vessel diameters, including the central retinal arteriolar equivalent (CRAE) and central retinal venular equivalent (CRVE), were calculated in micrometers (µm) using the six largest vessels with the revised Parr–Hubbard formula [38].

4.2.5. Biochemical Markers

Blood samples were collected and centrifuged at 800 rpm for 10 min without anticoagulants, and the resulting serum was stored at −80 °C. These samples were obtained to measure serum ADMA [11] and cotinine, to confirm recent tobacco exposure [39]. ADMA levels were determined using an ELISA kit from Immunodiagnostic AG (Bensheim, Germany), and cotinine was measured with a kit from Abnova (KA0930, Taipei, Taiwan), with a detection threshold set to differentiate between non-smokers, passive smokers, and active smokers.

4.3. Statistical Analysis

A priori sample size calculation based on differences in arterial stiffness [40] indicated that a minimum of 32 participants (16 former smokers and 16 non-smokers) were required to achieve 90% power at a 0.05 significance level for repeated measures across three time points, assuming a moderate effect size (f = 0.3), as determined using G*Power 3 [41]. Each participant underwent assessments at three gestational stages: early pregnancy (V1: 11–16 weeks), mid-pregnancy (V2: 24–28 weeks), and late pregnancy (V3: 34–37 weeks). Vascular parameters measured included cfPWV, ADMA, MAP, SBP, DBP, HR, CRAE, and CRVE. Data normality was verified using the Shapiro–Wilk test (p > 0.05) and Q–Q plots. Group comparisons were conducted using independent t-tests or Mann–Whitney U tests, as appropriate. For longitudinal analyses, mixed-effects models with Restricted Maximum Likelihood Estimation (REML) and the Geisser–Greenhouse correction were employed; Tukey’s test was used for post hoc comparisons. Due to challenges in longitudinal follow-up, sample sizes varied across time points, as not all participants completed each visit. Analyses were performed on available cases without imputation. Sensitivity analyses confirmed that the missing data did not introduce systematic bias. Mixed-effects models were applied, which are robust to unbalanced datasets under the assumption that data are missing at random (MAR). All tests were two-sided, with statistical significance set at p < 0.05. Data analyses were conducted using SPSS version 27.0, and figures were generated using GraphPad Prism version 9.

5. Conclusions

High-risk pregnancies demonstrate progressive endothelial and hemodynamic changes across gestation, with comparable vascular profiles between former smokers and lifelong non-smokers. Future studies should include active smokers, low-risk pregnancies, and detailed assessments of environmental and lifestyle exposures to fully elucidate the vascular impact of smoking history in pregnancy.

Supplementary Materials

The following supporting information can be downloaded at https://www.mdpi.com/article/10.3390/ijms26125781/s1.

Author Contributions

K.K.H., M.C.-Z. and N.G. designed the research, performed data acquisition, and pre-processed the data. M.C.-Z., C.S., K.M.-P., B.S. and M.N. contributed to data collection. A.S. and P.D.B. conducted the retinal image analysis. K.K.H. and K.E. analyzed the data and performed the statistical analysis. K.K.H. created the graphics and tables and drafted the original manuscript. K.K.H., U.H. and N.G. interpreted the results. K.K.H., M.C.-Z., M.N., U.H., A.S., P.D.B., B.S., C.S., K.M.-P. and N.G. reviewed and edited the manuscript. All authors accept responsibility for the paper as published. All authors have read and agreed to the published version of the manuscript.

Funding

This study was conducted as part of the institutional research at the Medical University of Graz, without external funding.

Institutional Review Board Statement

This study was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Review Board (Ethics Committee) of the Medical University of Graz (protocol code 31-541 ex 18/19; approval date: 17 October 2019). This study was registered on ClinicalTrials.gov (NCT06645340).

Informed Consent Statement

Informed consent was obtained from all subjects involved in this study.

Data Availability Statement

The datasets generated from the current study are available from the corresponding author on request.

Acknowledgments

We express our gratitude to all participants for their time and cooperation, as well as to the Gravitational Physiology and Medicine research team at the Medical University of Graz for their support throughout all processes involved in this study.

Conflicts of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  1. Barr, L.C.; Liblik, K.; Johri, A.M.; Smith, G.N. Maternal Cardiovascular Function Following a Pregnancy Complicated by Preeclampsia. Am. J. Perinatol. 2022, 39, 1055–1064. [Google Scholar] [CrossRef] [PubMed]
  2. American College of Obstetricians and Gynecologists. Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. Obstet. Gynecol. 2020, 135, e237–e260. [Google Scholar] [CrossRef] [PubMed]
  3. Duley, L. The global impact of pre-eclampsia and eclampsia. Semin. Perinatol. 2009, 33, 130–137. [Google Scholar] [CrossRef] [PubMed]
  4. Rana, S.; Lemoine, E.; Granger, J.P.; Karumanchi, S.A. Preeclampsia: Pathophysiology, Challenges, and Perspectives. Circ. Res. 2019, 124, 1094–1112, Erratum in Circ Res. 2020, 126, e8. [Google Scholar] [CrossRef]
  5. Soullane, S.; Rhéaume, M.-A.; Auger, N. Preeclampsia and the Retina. Curr. Hypertens. Rep. 2024, 26, 169–174. [Google Scholar] [CrossRef]
  6. Brown, M.A.; Magee, L.A.; Kenny, L.C.; Karumanchi, S.A.; McCarthy, F.P.; Saito, S.; Hall, D.R.; Warren, C.E.; Adoyi, G.; Ishaku, S.; et al. The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens. 2018, 13, 291–310. [Google Scholar] [CrossRef]
  7. Poon, L.C.; Shennan, A.; Hyett, J.A.; Kapur, A.; Hadar, E.; Divakar, H.; McAuliffe, F.; da Silva Costa, F.; von Dadelszen, P.; McIntyre, H.D.; et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention. Int. J. Gynaecol. Obstet. 2019, 145 (Suppl. S1), 1–33, Erratum in Int. J. Gynaecol. Obstet. 2019, 146, 390–391. [Google Scholar] [CrossRef]
  8. Rolnik, D.L.; Wright, D.; Poon, L.C.Y.; Syngelaki, A.; O’Gorman, N.; de Paco Matallana, C.; Akolekar, R.; Cicero, S.; Janga, D.; Singh, M.; et al. ASPRE trial: Performance of screening for preterm pre-eclampsia. Ultrasound Obstet. Gynecol. 2017, 50, 492–495, Erratum in Ultrasound Obstet. Gynecol. 2017, 50, 807. [Google Scholar] [CrossRef]
  9. Qu, H.; Khalil, R.A. Vascular mechanisms and molecular targets in hypertensive pregnancy and preeclampsia. Am. J. Physiol. Heart Circ. Physiol. 2020, 319, H661–H681. [Google Scholar] [CrossRef]
  10. Gyselaers, W. Hemodynamic pathways of gestational hypertension and preeclampsia. Am. J. Obstet. Gynecol. 2022, 226, S988–S1005. [Google Scholar] [CrossRef] [PubMed]
  11. Portelli, M.; Baron, B. Clinical Presentation of Preeclampsia and the Diagnostic Value of Proteins and Their Methylation Products as Biomarkers in Pregnant Women with Preeclampsia and Their Newborns. J. Pregnancy 2018, 2018, 2632637. [Google Scholar] [CrossRef] [PubMed]
  12. Messner, B.; Bernhard, D. Smoking and cardiovascular disease: Mechanisms of endothelial dysfunction and early atherogenesis. Arterioscler. Thromb. Vasc. Biol. 2014, 34, 509–515. [Google Scholar] [CrossRef] [PubMed]
  13. Klein, J.; Diaba-Nuhoho, P.; Giebe, S.; Brunssen, C.; Morawietz, H. Regulation of endothelial function by cigarette smoke and next-generation tobacco and nicotine products. Pflügers Arch. 2023, 475, 835–844. [Google Scholar] [CrossRef] [PubMed]
  14. Ambrose, J.A.; Barua, R.S. The pathophysiology of cigarette smoking and cardiovascular disease: An update. J. Am. Coll. Cardiol. 2004, 43, 1731–1737. [Google Scholar] [CrossRef]
  15. Katsiki, N.; Papadopoulou, S.K.; Fachantidou, A.I.; Mikhailidis, D.P. Smoking and vascular risk: Are all forms of smoking harmful to all types of vascular disease? Public Health 2013, 127, 435–441. [Google Scholar] [CrossRef]
  16. Di, H.-K.; Gan, Y.; Lu, K.; Wang, C.; Zhu, Y.; Meng, X.; Xia, W.-Q.; Xu, M.-Z.; Feng, J.; Tian, Q.-F.; et al. Maternal smoking status during pregnancy and low birth weight in offspring: Systematic review and meta-analysis of 55 cohort studies published from 1986 to 2020. World J. Pediatr. 2022, 18, 176–185. [Google Scholar] [CrossRef]
  17. Shobeiri, F.; Jenabi, E. Smoking and placenta previa: A meta-analysis. J. Matern.-Fetal Neonatal Med. 2017, 30, 2985–2990. [Google Scholar] [CrossRef]
  18. Wei, J.; Liu, C.-X.; Gong, T.-T.; Wu, Q.-J.; Wu, L. Cigarette smoking during pregnancy and preeclampsia risk: A systematic review and meta-analysis of prospective studies. Oncotarget 2015, 6, 43667–43678. [Google Scholar] [CrossRef]
  19. Conde-Agudelo, A.; Althabe, F.; Belizán, J.M.; Kafury-Goeta, A.C. Cigarette smoking during pregnancy and risk of preeclampsia: A systematic review. Am. J. Obstet. Gynecol. 1999, 181, 1026–1035. [Google Scholar] [CrossRef]
  20. Braekke, K.; Ueland, P.M.; Harsem, N.K.; Staff, A.C. Asymmetric dimethylarginine in the maternal and fetal circulation in preeclampsia. Pediatr. Res. 2009, 66, 411–415. [Google Scholar] [CrossRef]
  21. Akhter, T.; Wikström, G.; Larsson, M.; Bondesson, U.; Hedeland, M.; Naessen, T. Dimethylarginines correlate to common carotid artery wall layer dimensions and cardiovascular risk factors in pregnant women with/without preeclampsia: A group comparative study. Eur. J. Obstet. Gynecol. Reprod. Biol. 2021, 258, 288–293. [Google Scholar] [CrossRef] [PubMed]
  22. Bian, Z.; Shixia, C.; Duan, T. First-Trimester Maternal Serum Levels of sFLT1, PGF and ADMA Predict Preeclampsia. PLoS ONE 2015, 10, e0124684. [Google Scholar] [CrossRef] [PubMed]
  23. Yousif, D.; Bellos, I.; Penzlin, A.I.; Hijazi, M.M.; Illigens, B.M.-W.; Pinter, A.; Siepmann, T. Autonomic Dysfunction in Preeclampsia: A Systematic Review. Front. Neurol. 2019, 10, 816. [Google Scholar] [CrossRef] [PubMed]
  24. Simanjuntak, M.K.; Idris, I.; Sunarno, I.; Arifuddin, S.; Sinrang, A.W. Mean arterial pressure and the endothelin-1 levels in preeclampsia. Gac. Sanit. 2021, 35 (Suppl. S2), S242–S244. [Google Scholar] [CrossRef]
  25. Hausvater, A.; Giannone, T.; Sandoval, Y.-H.G.; Doonan, R.J.; Antonopoulos, C.N.; Matsoukis, I.L.; Petridou, E.T.; Daskalopoulou, S.S. The association between preeclampsia and arterial stiffness. J. Hypertens. 2012, 30, 17–33. [Google Scholar] [CrossRef]
  26. Ferreira, A.F.; Azevedo, M.J.; Morais, J.; Trindade, F.; Saraiva, F.; Diaz, S.O.; Alves, I.N.; Fragão-Marques, M.; Sousa, C.; Machado, A.P.; et al. Cardiovascular risk factors during pregnancy impact the postpartum cardiac and vascular reverse remodeling. Am. J. Physiol. Heart Circ. Physiol. 2023, 325, H774–H789, Erratum in Am. J. Physiol. Heart Circ. Physiol. 2024, 326, H1060. [Google Scholar] [CrossRef]
  27. Ding, J.; Wai, K.L.; McGeechan, K.; Ikram, M.K.; Kawasaki, R.; Xie, J.; Klein, R.; Klein, B.B.; Cotch, M.F.; Wang, J.J.; et al. Retinal vascular caliber and the development of hypertension: A meta-analysis of individual participant data. J. Hypertens. 2014, 32, 207–215. [Google Scholar] [CrossRef]
  28. Osman, M.W.; Nath, M.; Khalil, A.; Webb, D.R.; Robinson, T.G.; Mousa, H.A. Longitudinal study to assess changes in arterial stiffness and cardiac output parameters among low-risk pregnant women. Pregnancy Hypertens. 2017, 10, 256–261. [Google Scholar] [CrossRef]
  29. Green, L.J.B.; Mackillop, L.H.M.; Salvi, D.; Pullon, R.; Loerup, L.; Tarassenko, L.; Mossop, J.B.; Edwards, C.B.; Gerry, S.M.; Birks, J.M.; et al. Gestation-Specific Vital Sign Reference Ranges in Pregnancy. Obstet. Gynecol. 2020, 135, 653–664. [Google Scholar] [CrossRef]
  30. Li, L.-J.; Cheung, C.Y.-L.; Ikram, M.K.; Gluckman, P.; Meaney, M.J.; Chong, Y.-S.; Kwek, K.; Wong, T.-Y.; Saw, S.-M. Blood pressure and retinal microvascular characteristics during pregnancy: Growing Up in Singapore Towards Healthy Outcomes (GUSTO) Study. Hypertension 2012, 60, 223–230. [Google Scholar] [CrossRef]
  31. Rizos, D.; Eleftheriades, M.; Batakis, E.; Rizou, M.; Haliassos, A.; Hassiakos, D.; Botsis, D. Levels of asymmetric dimethylarginine throughout normal pregnancy and in pregnancies complicated with preeclampsia or had a small for gestational age baby. J. Matern.-Fetal Neonatal Med. 2012, 25, 1311–1315. [Google Scholar] [CrossRef] [PubMed]
  32. Holden, D.P.; Fickling, S.A.; Whitley, G.S.; Nussey, S.S. Plasma concentrations of asymmetric dimethylarginine, a natural inhibitor of nitric oxide synthase, in normal pregnancy and preeclampsia. Am. J. Obstet. Gynecol. 1998, 178, 551–556. [Google Scholar] [CrossRef] [PubMed]
  33. Mihuta, M.S.; Paul, C.; Borlea, A.; Cepeha, C.M.; Velea, I.P.; Mozos, I.; Stoian, D. The Oscillometric Pulse Wave Analysis Is Useful in Evaluating the Arterial Stiffness of Obese Children with Relevant Cardiometabolic Risks. J. Clin. Med. 2022, 11, 5078. [Google Scholar] [CrossRef] [PubMed]
  34. Hahad, O.; Schmitt, V.H.; Arnold, N.; Keller, K.; Prochaska, J.H.; Wild, P.S.; Schulz, A.; Lackner, K.J.; Pfeiffer, N.; Schmidtmann, I.; et al. Chronic cigarette smoking is associated with increased arterial stiffness in men and women: Evidence from a large population-based cohort. Clin. Res. Cardiol. 2023, 112, 270–284. [Google Scholar] [CrossRef]
  35. Chaemsaithong, P.; Sahota, D.S.; Poon, L.C. First trimester preeclampsia screening and prediction. Am. J. Obstet. Gynecol. 2022, 226, S1071–S1097.e2. [Google Scholar] [CrossRef]
  36. Müller, J.; Oberhoffer, R.; Barta, C.; Hulpke-Wette, M.; Hager, A. Oscillometric carotid to femoral pulse wave velocity estimated with the Vicorder device. J. Clin. Hypertens. 2013, 15, 176–179. [Google Scholar] [CrossRef]
  37. Khan, A.; De Boever, P.; Gerrits, N.; Akhtar, N.; Saqqur, M.; Ponirakis, G.; Gad, H.; Petropoulos, I.N.; Shuaib, A.; Faber, J.E.; et al. Retinal vessel multifractals predict pial collateral status in patients with acute ischemic stroke. PLoS ONE 2022, 17, e0267837. [Google Scholar] [CrossRef]
  38. Knudtson, M.D.; Lee, K.E.; Hubbard, L.D.; Wong, T.Y.; Klein, R.; Klein, B.E. Revised formulas for summarizing retinal vessel diameters. Curr. Eye Res. 2003, 27, 143–149. [Google Scholar] [CrossRef]
  39. Duque, A.; Martinez, P.; Giraldo, A.; Gualtero, D.; Ardila, C.; Contreras, A.; Duarte, S.; Lafaurie, G. Accuracy of cotinine serum test to detect the smoking habit and its association with periodontal disease in a multicenter study. Med. Oral. Patol. Oral. Cir. Bucal. 2017, 22, e425–e431. [Google Scholar] [CrossRef]
  40. Mannaerts, D.; Faes, E.; Goovaerts, I.; Stoop, T.; Cornette, J.; Gyselaers, W.J.; Spaanderman, M.E.A.; Van Craenenbroeck, E.M.; Jacquemyn, Y. Flow-mediated dilation and peripheral arterial tonometry are disturbed in preeclampsia and reflect different aspects of endothelial function. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2017, 313, R518–R525. [Google Scholar] [CrossRef]
  41. Faul, F.; Erdfelder, E.; Lang, A.-G.; Buchner, A. G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav. Res. Methods 2007, 39, 175–191. [Google Scholar] [CrossRef]
Figure 1. Hemodynamic and vascular parameters in former smokers and non-smokers during pregnancy. Longitudinal changes are shown in (A) ADMA, (B) MAP, (C) SBP, (D) DBP, (E) HR, (F) cfPWV, (G) CRVE, and (H) CRAE across early (V1, 11–16 weeks), mid (V2, 24–28 weeks), and late (V3, 34–37 weeks) pregnancy. Green lines represent non-smokers; orange lines represent former smokers. Data are presented as mean ± SD. Group comparisons at each visit were assessed using unpaired t-tests; significance was set at p <  0.05. Similar profiles were observed between groups at all time points (descriptive data with p value shown in Supplementary Table S2) without statistical significant differences. Abbreviations: ADMA, asymmetric dimethylarginine; MAP, mean arterial pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; cfPWV, carotid–femoral pulse wave velocity; CRAE, central retinal artery equivalent; and CRVE, central retinal vein equivalent.
Figure 1. Hemodynamic and vascular parameters in former smokers and non-smokers during pregnancy. Longitudinal changes are shown in (A) ADMA, (B) MAP, (C) SBP, (D) DBP, (E) HR, (F) cfPWV, (G) CRVE, and (H) CRAE across early (V1, 11–16 weeks), mid (V2, 24–28 weeks), and late (V3, 34–37 weeks) pregnancy. Green lines represent non-smokers; orange lines represent former smokers. Data are presented as mean ± SD. Group comparisons at each visit were assessed using unpaired t-tests; significance was set at p <  0.05. Similar profiles were observed between groups at all time points (descriptive data with p value shown in Supplementary Table S2) without statistical significant differences. Abbreviations: ADMA, asymmetric dimethylarginine; MAP, mean arterial pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; cfPWV, carotid–femoral pulse wave velocity; CRAE, central retinal artery equivalent; and CRVE, central retinal vein equivalent.
Ijms 26 05781 g001
Figure 2. Longitudinal changes in vascular and hemodynamic parameters in high-risk pregnancies across early (V1), mid (V2), and late (V3) gestation. Shown are plasma ADMA (A), MAP (B), SBP (C), DBP (D), HR (E), cfPWV (F), CRVE (G), and CRAE (H). ADMA and blood pressure parameters (MAP, SBP, DBP) increased progressively over gestation, while retinal vessel calibers (CRVE, CRAE) decreased significantly in late pregnancy. cfPWV remained unchanged. Data are presented as mean ± SD; individual values are shown as black dots. Statistical analysis was performed using mixed-effects models (REML) with Geisser–Greenhouse correction. Tukey’s test was applied for post hoc comparisons. p < 0.05 = *; p < 0.01 = **; p < 0.001= *** and ns = not significant (descriptive data with p value shown in Supplementary Table S1). Abbreviations: ADMA, asymmetric dimethylarginine; MAP, mean arterial pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; cfPWV, carotid–femoral pulse wave velocity; CRVE, central retinal vein equivalent; CRAE, central retinal artery equivalent; and REML, restricted maximum likelihood.
Figure 2. Longitudinal changes in vascular and hemodynamic parameters in high-risk pregnancies across early (V1), mid (V2), and late (V3) gestation. Shown are plasma ADMA (A), MAP (B), SBP (C), DBP (D), HR (E), cfPWV (F), CRVE (G), and CRAE (H). ADMA and blood pressure parameters (MAP, SBP, DBP) increased progressively over gestation, while retinal vessel calibers (CRVE, CRAE) decreased significantly in late pregnancy. cfPWV remained unchanged. Data are presented as mean ± SD; individual values are shown as black dots. Statistical analysis was performed using mixed-effects models (REML) with Geisser–Greenhouse correction. Tukey’s test was applied for post hoc comparisons. p < 0.05 = *; p < 0.01 = **; p < 0.001= *** and ns = not significant (descriptive data with p value shown in Supplementary Table S1). Abbreviations: ADMA, asymmetric dimethylarginine; MAP, mean arterial pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; cfPWV, carotid–femoral pulse wave velocity; CRVE, central retinal vein equivalent; CRAE, central retinal artery equivalent; and REML, restricted maximum likelihood.
Ijms 26 05781 g002
Figure 3. The schematic overview of the study design and assessments.
Figure 3. The schematic overview of the study design and assessments.
Ijms 26 05781 g003
Table 1. Baseline characteristics of the high-risk pregnancy cohort.
Table 1. Baseline characteristics of the high-risk pregnancy cohort.
CharacteristicValue
n/% (means ± SD)
Participants (n)43
Age (years)33.2 ± 4.4
BMI (kg/m2)26.4 ± 5.9
Gestational age at delivery (wk.)38 ± 2
Birth weight (grams)3108 ± 574
Nulliparous patients, n (%)16 (37.2%)
Previous smokeres/non-smokeres, n18/25
Ethnicity, n (%)
Caucasian42 (97.7%)
Black1 (2.3%)
Conception mode, n (%)
Spontaneous37 (86%)
IVF6 (14%)
Outcome, n (%)
Preeclampisa (PE)8 (18.6%)
Gestational dieabetes mellitus (GDM)6 (14%)
Gestational hypertention (GH)6 (14%)
No complications23 (53.5%)
Data are presented as mean ± standard deviation (SD) or as number (n) with corresponding percentages (%), as appropriate. Baseline characteristics including age, BMI, ethnicity, and mode of conception were recorded at enrollment. Pregnancy outcomes, including gestational age at delivery, birth weight, and complications, preeclampsia (PE), gestational diabetes mellitus (GDM), and gestational hypertension (GH), were documented at delivery.
Table 2. Longitudinal vascular and hemodynamic parameters across gestation in former smokers and non-smokers.
Table 2. Longitudinal vascular and hemodynamic parameters across gestation in former smokers and non-smokers.
ParameterStageFormer Smokers
(n = 18)
n/% (means ± SD)
P
(V1 vs. V2 vs. V3)
Non-Smokers
(n = 25)
n/% (means ± SD)
P
(V1 vs. V2 vs. V3)
ADMA (μmol/L)V118/100 (0.44 ± 0.03)0.23125/100 (0.45 ± 0.05)0.020
V212/67 (0.45 ± 0.05)20/80 (0.45 ± 0.07)
V39/50 (0.45 ± 0.02)18/72 (0.49 ± 0.07)
HR (b/min)V113/72 (80.18 ± 9.2)0.05720/80 (76.95 ± 10.5)0.050
V29/50 (88.00 ± 11.6)14/56 (84.0 ± 15.3)
V37/34 (86.71 ± 13.0)8/32 (91.00 ± 15.5)
MAP (mmHg)V113/72 (92.3 ± 11.7)0.23620/80 (91.2 ± 11.2)0.001
V29/50 (87.3 ± 13.7)14/56 (88.5 ± 9.7)
V37/34 (92.1 ± 12.1)8/32 (105 ±9.7)
SBP (mmHg)V113/72 (133.8 ± 1.78)0.17720/80 (129.0 ± 15.5)0.186
V29/50 (122.7 ± 16.8)14/56 (125.1 ± 10.8)
V37/34 (129.0 ± 21.8)8/32 (134.1 ± 10.4)
DBP (mmHg)V113/72 (71.58 ± 10.13)0.23420/80 (72.3 ± 9.7)0.0001
V29/50 (66.3 ± 7.4)14/56 (70.1 ± 9.5)
V37/34 (73.7 ± 9.5)8/32 (83.7 ± 9.7)
CRAE (µm)V110/56 (140.9 ± 17.5)0.52719/76 (146.2 ± 15.1)0.058
V29/50 (146.6 ± 19.0)14/56 (149.7 ± 18.3)
V36/34 (139.4 ± 21.6)10/40 (142.8 ± 13.9)
CRVE (µm)V110/56 (221.0 ± 15.6)0.46219/76 (224.0 ± 21.6)0.186
V29/50 (227.9 ± 14.8)14/56 (225.6 ± 24.2)
V36/34 (223.0 ± 16.7)10/40 (219.7 ± 22.2)
cfPWV (m/s)V113/72 (7.72 ± 1.0)0.56820/80 (7.78 ± 1.2)0.4370
V29/50 (7.45 ± 0.7)14/56 (7.28 ± 1.3)
V37/34 (7.31 ± 1.4)8/32 (7.20 ± 1.1)
Data are shown as the mean ± SD at each visit (V1: 11–16 weeks; V2: 24–28 weeks; and V3: 34–37 weeks). A statistical analysis was performed using mixed-effects models with a restricted maximum likelihood (REML) estimation to assess differences across visits within each group. p-values indicate the significance of the change across timepoints (V1 vs. V2 vs. V3) within each group. A p < 0.05 was considered statistically significant. CRAE = central retinal arteriolar equivalent; CRVE = central retinal venular equivalent; cfPWV = carotid–femoral pulse wave velocity; ADMA = asymmetric dimethylarginine; MAP = mean arterial pressure; SBP = systolic blood pressure; DBP = diastolic blood pressure; and HR = heart rate.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Kutllovci Hasani, K.; Cervar-Zivkovic, M.; Hiden, U.; Saloň, A.; Nanda, M.; Steuber, B.; Eberhard, K.; De Boever, P.; Stern, C.; Mayer-Pickel, K.; et al. Maternal Vascular Adaptation in High-Risk Pregnancies: Effects of Early Smoking Cessation on Hemodynamic and Endothelial Function. Int. J. Mol. Sci. 2025, 26, 5781. https://doi.org/10.3390/ijms26125781

AMA Style

Kutllovci Hasani K, Cervar-Zivkovic M, Hiden U, Saloň A, Nanda M, Steuber B, Eberhard K, De Boever P, Stern C, Mayer-Pickel K, et al. Maternal Vascular Adaptation in High-Risk Pregnancies: Effects of Early Smoking Cessation on Hemodynamic and Endothelial Function. International Journal of Molecular Sciences. 2025; 26(12):5781. https://doi.org/10.3390/ijms26125781

Chicago/Turabian Style

Kutllovci Hasani, Kaltrina, Mila Cervar-Zivkovic, Ursula Hiden, Adam Saloň, Manurishi Nanda, Bianca Steuber, Katharina Eberhard, Patrick De Boever, Christina Stern, Karoline Mayer-Pickel, and et al. 2025. "Maternal Vascular Adaptation in High-Risk Pregnancies: Effects of Early Smoking Cessation on Hemodynamic and Endothelial Function" International Journal of Molecular Sciences 26, no. 12: 5781. https://doi.org/10.3390/ijms26125781

APA Style

Kutllovci Hasani, K., Cervar-Zivkovic, M., Hiden, U., Saloň, A., Nanda, M., Steuber, B., Eberhard, K., De Boever, P., Stern, C., Mayer-Pickel, K., & Goswami, N. (2025). Maternal Vascular Adaptation in High-Risk Pregnancies: Effects of Early Smoking Cessation on Hemodynamic and Endothelial Function. International Journal of Molecular Sciences, 26(12), 5781. https://doi.org/10.3390/ijms26125781

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop